Physician profile
Ashlee Fish
NPI 1225435902
$4,835.40
in general payments reported to CMS, 2019-2025
29 companies · $83.51 in 2025
The $83.51 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,053 · 2022: $1,353 · 2023: $1,343 · 2024: $1,003 · 2025: $83.51.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,330 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,329.55 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,018.54 | 2022-2025 | |
| Pfizer INC. | $605.63 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $564.74 | 2021-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $386.44 | 2021-2025 | Verquvo, Capvaxive |
| Amgen INC. | $357.46 | 2021-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals Lp | $345.62 | 2021-2024 | Brilinta, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $331.01 | 2021-2024 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $275.76 | 2021-2024 | Eliquis, Camzyos |
| Abiomed | $137.88 | 2021-2024 | Impella |
| Medicomp INC | $116.70 | 2022-2024 | Telepatch Cardiac Monitor |
| Medtronic, INC. | $108.65 | 2021 | |
| Alnylam Pharmaceuticals INC. | $103.95 | 2021-2024 | Onpattro |
| Heartflow, INC. | $63.20 | 2024 | |
| Abbott Laboratories | $56.94 | 2021-2023 | Thoratec Heartmate 3 Lvas Implant Kit |
| Novo Nordisk INC | $50.57 | 2023 | Wegovy |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $46.64 | 2021 | |
| Chiesi USA, INC. | $38.41 | 2022-2024 | Kengreal |
| Philips North America LLC | $31.84 | 2023 | |
| Lexicon Pharmaceuticals, INC. | $24.12 | 2024 | |
| Itamar Medical INC | $22.65 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $22.08 | 2024 | Uptravi |
| Boston Scientific Corporation | $20.65 | 2023 | Watchman Access System |
| Daiichi Sankyo INC. | $18.60 | 2024 | Injectafer |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $16.67 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $16.19 | 2025 | Rexulti |
| Alexion Pharmaceuticals, INC. | $14.89 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $14.06 | 2024 | Arcalyst |
| Kiniksa Pharmaceuticals, Ltd. | $13.92 | 2023 | Arcalyst |
| Shockwave Medical, INC | $11.59 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashlee Fish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.